SCHEMBL23770632

SCHEMBL23770632

Fc1ccc(-c2nc(NSc3cccc(N4CCNCC4)n3)ccc2C(F)(F)F)c(Cl)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB2 P07550 1/20 0.42
HTR3E A5X5Y0 1/20 0.37
HTR3B O95264 1/20 0.37
ALDH1A1 P00352 1/20 0.37
HTR3A P46098 1/20 0.37
HTR3D Q70Z44 1/20 0.37
HTR3C Q8WXA8 1/20 0.37
CYP1A2 P05177 2/20 0.37
CYP2C9 P11712 1/20 0.37
BPTF Q12830 1/20 0.35
CYP2C19 P33261 1/20 0.35
KARS1 Q15046 1/20 0.33
HSD11B1 P28845 1/20 0.33
CTSL P07711 1/20 0.33
CTSK P43235 1/20 0.33
CTSC P53634 1/20 0.33
CNR2 P34972 3/20 0.33
CNR1 P21554 1/20 0.33
KCNH2 Q12809 1/20 0.32
MAPK14 Q16539 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23770669 0.90 HTR3A (0.40) HTR3EHTR3BALDH1A1HTR3AHTR3D
SCHEMBL23770770 0.88 ADRB2 (0.38) ADRB2HTR3EHTR3BALDH1A1HTR3A
SCHEMBL23770489 0.86 HSD11B1 (0.33) HSD11B1CNR2CNR1WDR5KRAS
SCHEMBL23770606 0.86 ADRB2 (0.43) ADRB2HTR3EHTR3BALDH1A1HTR3A
SCHEMBL23770651 0.84 RORC (0.38) HSD11B1CNR2CNR1KCNH2PTPN11
SCHEMBL23770453 0.82 CYP1A2 (0.40) ADRB2HTR3EHTR3BALDH1A1HTR3A
SCHEMBL23770663 0.82 CYP1A2 (0.43) ADRB2HTR3EHTR3BALDH1A1HTR3A
SCHEMBL23770560 0.81 CYP1A2 (0.45) ADRB2HTR3EHTR3BALDH1A1HTR3A
SCHEMBL19927792 0.81 ADRB2 (0.41) ADRB2HTR3EHTR3BALDH1A1HTR3A
SCHEMBL29464363 0.81 ADRB2 (0.41) ADRB2HTR3EHTR3BALDH1A1HTR3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3504194-B1 N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE NOVARTIS AG (CH) 2021-08-18 EP disclosed